204 related articles for article (PubMed ID: 11520816)
1. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Das H; Wang L; Kamath A; Bukowski JF
Blood; 2001 Sep; 98(5):1616-8. PubMed ID: 11520816
[TBL] [Abstract][Full Text] [Related]
2. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen.
Miyagawa F; Tanaka Y; Yamashita S; Minato N
J Immunol; 2001 May; 166(9):5508-14. PubMed ID: 11313389
[TBL] [Abstract][Full Text] [Related]
3. Contribution of Complementarity-Determining Region 3 of the T-Cell Receptor Vδ2 Chain to the Recognition of Aminobisphosphonates by Human γδ T-Cells.
Nishimura H; Hirokawa M; Fujishima N; Fujishima M; Miura I; Sawada K
Int J Hematol; 2004 May; 79(4):369-76. PubMed ID: 15218968
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.
Kunzmann V; Bauer E; Feurle J; Weissinger F; Tony HP; Wilhelm M
Blood; 2000 Jul; 96(2):384-92. PubMed ID: 10887096
[TBL] [Abstract][Full Text] [Related]
5. Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism.
Wang H; Sarikonda G; Puan KJ; Tanaka Y; Feng J; Giner JL; Cao R; Mönkkönen J; Oldfield E; Morita CT
J Immunol; 2011 Nov; 187(10):5099-113. PubMed ID: 22013129
[TBL] [Abstract][Full Text] [Related]
6. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo.
Kabelitz D; Wesch D; Pitters E; Zöller M
J Immunol; 2004 Dec; 173(11):6767-76. PubMed ID: 15557170
[TBL] [Abstract][Full Text] [Related]
7. Involvement of CD166 in the activation of human gamma delta T cells by tumor cells sensitized with nonpeptide antigens.
Kato Y; Tanaka Y; Hayashi M; Okawa K; Minato N
J Immunol; 2006 Jul; 177(2):877-84. PubMed ID: 16818742
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate therapy.
Licata AA
Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162
[TBL] [Abstract][Full Text] [Related]
9. Requirement of species-specific interactions for the activation of human gamma delta T cells by pamidronate.
Kato Y; Tanaka Y; Tanaka H; Yamashita S; Minato N
J Immunol; 2003 Apr; 170(7):3608-13. PubMed ID: 12646624
[TBL] [Abstract][Full Text] [Related]
10. An update on bisphosphonates.
Cohen SB
Curr Rheumatol Rep; 2004 Feb; 6(1):59-65. PubMed ID: 14713403
[TBL] [Abstract][Full Text] [Related]
11. Conservation of nonpeptide antigen recognition by rhesus monkey V gamma 2V delta 2 T cells.
Wang H; Lee HK; Bukowski JF; Li H; Mariuzza RA; Chen ZW; Nam KH; Morita CT
J Immunol; 2003 Apr; 170(7):3696-706. PubMed ID: 12646635
[TBL] [Abstract][Full Text] [Related]
12. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
Dhar S; Chiplunkar SV
Cancer Immun; 2010 Nov; 10():10. PubMed ID: 21069948
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells.
Okuno D; Sugiura Y; Sakamoto N; Tagod MSO; Iwasaki M; Noda S; Tamura A; Senju H; Umeyama Y; Yamaguchi H; Suematsu M; Morita CT; Tanaka Y; Mukae H
Front Immunol; 2020; 11():1405. PubMed ID: 32793196
[TBL] [Abstract][Full Text] [Related]
14. Crucial role of TCR gamma chain junctional region in prenyl pyrophosphate antigen recognition by gamma delta T cells.
Bukowski JF; Morita CT; Band H; Brenner MB
J Immunol; 1998 Jul; 161(1):286-93. PubMed ID: 9647235
[TBL] [Abstract][Full Text] [Related]
15. Human TCR-gamma/delta alloreactive response to HLA-DR molecules. Comparison with response of TCR-alpha/beta.
Flament C; Benmerah A; Bonneville M; Triebel F; Mami-Chouaib F
J Immunol; 1994 Oct; 153(7):2890-904. PubMed ID: 8089476
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates for osteoporosis.
Drug Ther Bull; 2001 Sep; 39(9):68-72. PubMed ID: 11586803
[TBL] [Abstract][Full Text] [Related]
17. Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity.
Spada FM; Grant EP; Peters PJ; Sugita M; Melián A; Leslie DS; Lee HK; van Donselaar E; Hanson DA; Krensky AM; Majdic O; Porcelli SA; Morita CT; Brenner MB
J Exp Med; 2000 Mar; 191(6):937-48. PubMed ID: 10727456
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates: preclinical aspects and use in osteoporosis.
Fleisch HA
Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD
Treat Endocrinol; 2005; 4(2):115-25. PubMed ID: 15783248
[TBL] [Abstract][Full Text] [Related]
20. Role of alendronate and risedronate in preventing and treating osteoporosis.
Peters ML; Leonard M; Licata AA
Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
